Heritage Trust Co Sells 18,136 Shares of Bristol Myers Squibb Company $BMY

Heritage Trust Co lessened its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 72.4% in the fourth quarter, HoldingsChannel reports. The fund owned 6,901 shares of the biopharmaceutical company’s stock after selling 18,136 shares during the period. Heritage Trust Co’s holdings in Bristol Myers Squibb were worth $372,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the company. Northwestern Mutual Investment Management Company LLC boosted its holdings in shares of Bristol Myers Squibb by 0.3% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company’s stock worth $3,509,000 after acquiring an additional 172 shares during the period. ESG Planning DBA Harper Investing raised its position in shares of Bristol Myers Squibb by 1.3% in the fourth quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company’s stock valued at $745,000 after buying an additional 180 shares in the last quarter. Novem Group raised its position in shares of Bristol Myers Squibb by 2.9% in the fourth quarter. Novem Group now owns 6,402 shares of the biopharmaceutical company’s stock valued at $345,000 after buying an additional 183 shares in the last quarter. Dominguez Wealth Management Solutions Inc. raised its position in shares of Bristol Myers Squibb by 0.8% in the fourth quarter. Dominguez Wealth Management Solutions Inc. now owns 22,404 shares of the biopharmaceutical company’s stock valued at $1,208,000 after buying an additional 185 shares in the last quarter. Finally, McLean Asset Management Corp raised its position in shares of Bristol Myers Squibb by 3.1% in the fourth quarter. McLean Asset Management Corp now owns 6,465 shares of the biopharmaceutical company’s stock valued at $369,000 after buying an additional 192 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb won expanded EU approval for Opdivo in combination with AVD as a frontline treatment for newly diagnosed advanced classical Hodgkin lymphoma, which could broaden use of one of its key cancer drugs. BMY Gets Opdivo Label Expansion in the EU, Update on Camzyos
• Positive Sentiment: The FDA accepted Camzyos for priority review in adolescents with symptomatic obstructive hypertrophic cardiomyopathy, signaling a potential label expansion that could open a new patient population for the drug. FDA Accepts Camzyos Supplemental New Drug Application
• Positive Sentiment: Recent ASCO data highlighted progress in BMY’s late-stage pipeline, including mezigdomide and pumitamig, reinforcing the company’s growth story beyond legacy products. Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO
• Neutral Sentiment: Unusual options activity showed traders buying a large number of call options, which can reflect speculation that more positive news could continue, but it does not by itself confirm a fundamental change.
• Negative Sentiment: Some commentary remains cautious, noting that BMY still faces patent-expiration headwinds through 2028 and that its stock may not be as cheap as it appears on traditional valuation measures. Why Bristol Myers Squibb Stock Isn’t Nearly As Cheap As It Looks

Analyst Ratings Changes

BMY has been the subject of a number of analyst reports. UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Cantor Fitzgerald lifted their price target on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a research report on Wednesday, April 8th. Bank of America dropped their price target on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. Morgan Stanley reiterated an “underweight” rating and issued a $40.00 price target on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Finally, HSBC lifted their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research report on Tuesday, March 17th. Eight equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Stock Down 1.1%

Shares of BMY opened at $54.34 on Wednesday. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The company has a market cap of $110.97 billion, a P/E ratio of 15.26, a P/E/G ratio of 0.16 and a beta of 0.24. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The firm has a 50 day simple moving average of $58.25 and a two-hundred day simple moving average of $56.37.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. During the same period in the previous year, the business earned $1.80 earnings per share. The company’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts forecast that Bristol Myers Squibb Company will post 6.31 EPS for the current fiscal year.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.05% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.